RxDoctor Payments Data

David Goldman, MD

Ophthalmology · Palm Beach Gardens, FLNPI 1871538116

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by AbbVie at 37.7% of the total. Reporting peaked in 2020 at $54,179 and has fallen 65.5% since, to $18,684 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$238,695in general payments, 2019–2025

Across 669 payments — averaging $356.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$90K
  • Rayner Intraocular Lenses Limited$61K
  • Alcon$14K
  • Carl Zeiss Meditec, Inc.$11K
  • Sight Sciences, Inc.$10K
  • Ocular Therapeutix, Inc.$9K
  • plus $43K from 32 others
$8,680in research payments, 2019–2025

Across 6 payments — averaging $1446.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$9K

What the payments were for

  • Consulting fees$71,39930%
  • Speaking & faculty fees$141,20659%
  • Travel & lodging$4,2372%
  • Food & beverage$19,0858%
  • Education$2,6881%
  • Gifts$640%
  • Other$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$238,695 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida →

Medicare billing

Part B allowed, 2024
$1,275,851
Medicare patients
3,913
Services billed
8,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine138$102,634
LumiganBimatoprost67$40,573
XiidraLifitegrast27$25,008
MieboPerfluorohexyloctane/Pf16$16,961
CombiganBrimonidine Tartrate/Timolol17$11,663
Latanoprost983$10,639
Travoprost43$10,446
VyzultaLatanoprostene Bunod14$10,245
Timolol Maleate207$9,527
Cyclosporine36$9,237
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol33$7,040
Prednisolone Acetate171$6,675
Tobramycin-DexamethasoneTobramycin/Dexamethasone137$6,387
Brimonidine Tartrate105$5,483
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat202$3,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$89,886$154,869222 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$1,162$52,21457 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$5,288$1,78213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Palm Beach Gardens

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →